Biotechnology Use and Development Survey
Results
Results
All (57)
All (57) (0 to 10 of 57 results)
- 1. Biotechnology use and development survey, indicators for innovative biotechnology firms by firm size ArchivedTable: 27-10-0266-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by firms size for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 2. Biotechnology use and development survey, indicators for innovative biotechnology firms by sector ArchivedTable: 27-10-0267-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by sector, for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 3. Biotechnology use and development survey, indicators for innovative biotechnology firms by region ArchivedTable: 27-10-0268-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms for Canada and by region , biennial survey from 1999 to 2005.Release date: 2008-09-26
- Articles and reports: 88F0006X2007007Description: Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.
This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.
Release date: 2007-12-20 - Articles and reports: 88F0006X2007006Description: This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.Release date: 2007-12-05
- 6. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210324Geography: CanadaDescription:
Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210325Geography: CanadaDescription:
Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2007005Description: This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.Release date: 2007-08-31
Data (3)
Data (3) ((3 results))
- 1. Biotechnology use and development survey, indicators for innovative biotechnology firms by firm size ArchivedTable: 27-10-0266-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by firms size for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 2. Biotechnology use and development survey, indicators for innovative biotechnology firms by sector ArchivedTable: 27-10-0267-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms by sector, for Canada, biennial survey from 1999 to 2005.Release date: 2008-09-26
- 3. Biotechnology use and development survey, indicators for innovative biotechnology firms by region ArchivedTable: 27-10-0268-01Frequency: Every 2 yearsDescription: Biotechnology use and development survey, indicators for innovative biotechnology firms for Canada and by region , biennial survey from 1999 to 2005.Release date: 2008-09-26
Analysis (54)
Analysis (54) (40 to 50 of 54 results)
- 41. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - Articles and reports: 88F0006X2001011Description:
This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.
Release date: 2001-08-28 - Articles and reports: 88-001-X20010047917Description:
Biotechnology is an enabling technology - one that has been compared to electricity or microelectronics - because it has the potential to transform production processes, products and services in a wide range of sectors of the economy. At present, major applications of biotechnology are taking place in health, agriculture and agrifood, and natural resources (e.g. forestry and mining). This survey is intended to quantify the level of industrial activity in biotechnology research and development by sector of application and to reveal trends in spending.
Release date: 2001-05-18 - Articles and reports: 88-003-X20010025752Geography: CanadaDescription:
With revenues of almost $2 billion, what are the characteristics and activities of firms that use or develop biotechnology as an important part of their firm's activities? Human Health biotechnology dominates both the revenue and spending in the biotechnology sector. Read this enlightening article for further details including dicussion on the geographic location and size of Canadian biotechnology firms.
Release date: 2001-05-02 - 45. Biotechnology Use and Development - 1999 ArchivedArticles and reports: 88F0006X2001007Description:
This paper provides estimates for firms actively involved in the development of new products and processes using biotechnologies. The survey examines the use of biotechnology and the development of biotechnologies in Canada's industrial sector for the 1999 fiscal year. The Biotechnology Use and Development Survey - 1999 was conducted as part of a project to develop biotechnology statistics and was funded under the Canadian Biotechnology Strategy. Several departments and agencies provided important inputs at various stages of the survey. They are Industry Canada, the Canadian Biotechnology Secretariat, Agriculture Canada, the National Research Council, the Canadian Institutes for Health Research, Natural Resources Canada, Department of Foreign Affairs and International Trade, Health Canada, and Environment Canada.
Release date: 2001-03-30 - 46. Internationally Comparable Indicators on Biotechnology: A Stocktaking, a Proposal for Work and Supporting Material ArchivedArticles and reports: 88F0017M2001009Geography: CanadaDescription:
This paper examines the call for an international effort to co-ordinate the measuring of biotechnology so that the ensuing statistics and indicators maintain some level of international comparability.
Release date: 2001-02-15 - Articles and reports: 88-003-X20000035770Geography: CanadaDescription:
Given the high cost of R&D, adopting the correct strategies and mix of products is required for success for Canadian biotechnology firms. A recent survey examined the rapid growth of 30 companies. Fast-growing enterprises adopted a strategy of patenting their products, avoiding major production delays, targeting export markets, accessing venture capital, conducting key alliances, and planning the IPO.
Release date: 2000-10-06 - Articles and reports: 88F0017M2000008Geography: CanadaDescription:
This report examines the factors contributing to the rapid growth of a small number of biotechnology firms in Canada.
Release date: 2000-08-28 - Articles and reports: 88-001-X20000027928Description:
The statistics presented in this bulletin are derived from our latest survey of research and development activities in Canadian industry. In 1997, a decision was made to reduce response burden by eliminating the short survey forms in favour of using administrative data. Biotechnology data are not currently available from administrative data. Therefore, only those research and development performers with over one million dollars of intramural research and development expenditures are included in these statistics. Based on 1995, the last year of full coverage, 87.6% of biotechnology research and development expenditures were made by these large performers, which represented 24% of all companies reporting biotechnology research and development activities.
Release date: 2000-06-16 - Articles and reports: 88-003-X19990025345Geography: CanadaDescription:
Some analysts suggest that biotechnology may trigger a revolution equal to the one prompted by information technology. Various sectors of Canadian industry are already actively using biotechnologies for purposes ranging from research and development to pollution control. Many still see obstacles to adopting new biotechnologies including lack of information and government regulation.
Release date: 2000-01-17
- Previous Go to previous page of Analysis results
- 1 Go to page 1 of Analysis results
- 2 Go to page 2 of Analysis results
- 3 Go to page 3 of Analysis results
- 4 Go to page 4 of Analysis results
- 5 (current) Go to page 5 of Analysis results
- 6 Go to page 6 of Analysis results
- Next Go to next page of Analysis results
Reference (0)
Reference (0) (0 results)
No content available at this time.